Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has rolled out Levetiracetam Extended-Release 500mg and 750mg tablets to treat partial-onset seizures in patients with epilepsy.
Subscribe to our email newsletter
Watson’s Levetiracetam Extended-Release 500mg and 750mg tablets are generic equivalent to Keppra XR of UCB.
Keppra is an anti-epileptic drug which is indicated for the treatment of partial onset seizures in patients 16 years of age and older with epilepsy.
The launching of the drug follows approval from the US Food and Drug Administration (FDA) for Levetiracetam Extended-Release 500mg and 750mg tablets’ abbreviated new drug application (ANDA).